Metraipolis › archive › dc_8ef49827d6ca
A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity — Europe PMC PMID:37428804
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37428804
- DOI
- 10.1371/journal.pntd.0011392
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:58:01.746Z
- SHA-256 of the archived text
4070d4fd343c9f23f69471a6cee08f12a9458e091fba1e0be4605673dc0f8e93- Stable URL of this page
https://metraipolis.com/documento/dc_8ef49827d6ca
How to cite
A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity — Europe PMC PMID:37428804 — Europe PMC (en), https://europepmc.org/article/MED/37428804 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_8ef49827d6ca (Metraipolis archive dc_8ef49827d6ca, sha256 4070d4fd343c9f23f69471a6cee08f12a9458e091fba1e0be4605673dc0f8e93)
BibTeX
@misc{dc8ef49827d6ca,
title = {A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity — Europe PMC PMID:37428804},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37428804},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_8ef49827d6ca; sha256 4070d4fd343c9f23f69471a6cee08f12a9458e091fba1e0be4605673dc0f8e93},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37428804. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: The parasitic filariae responsible for onchocerciasis and lymphatic filariasis are host to an endosymbiotic bacterium, Wolbachia, which is essential to the fertility and development of the parasites. We performed a Phase-I pharmacokinetic, safety and food-effect study on single and multiple ascending doses of flubentylosin (ABBV-4083), a macrolide antibacterial with activity against Wolbachia, intended to sterilize and eliminate the parasites. Methods: Seventy-eight healthy adults were exposed to flubentylosin; 36 were exposed to single ascending 40, 100, 200, 400 or 1000 mg doses; 12 received 1000 mg in the food-effect part; and 30 received multiple ascending daily doses of 100 mg for 7 days, 200 mg for 7 or 14 days, or 400 mg for 7 or 14 days. Twenty-two subjects received placebo. Results: Maximum concentrations (Cmax) of flubentylosin were reached after 1-2 hours, with a half-life < 4 hours at doses ≤ 400 mg. Cmax and AUC increased in a more than dose-proportional manner, with similar exposure after multiple dose administration. The most frequently reported adverse events were nausea (8/78, 10%) and headache (6/78, 8%). Two subjects given a single dose of flubentylosin 1000 mg in the food-effect part experienced reversible asymptomatic ALT and AST elevations at Grade 2 or Grade 4, with no elevation in bilirubin, deemed related to study drug. The effect of food on exposure parameters was minimal. No treatment-related serious adverse events were reported. Discussion: Flubentylosin 400 mg for 14 days was the maximum tolerated dose in this first-in-human, Phase-I study in healthy adults. Based on preclinical pharmacokinetic/pharmacodynamic modeling, flubentylosin 400 mg once daily for 7 or 14 days is expected to be an effective dose. A Phase-II, proof-of-concept study with flubentylosin using these regimens is currently ongoing in patients with onchocerciasis in Africa. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS neglected tropical diseases, 2023 (prima pubblicazione 2023-07-10). Identificativi: PMID 37428804 · PMCID PMC10368248 · DOI 10.1371/journal.pntd.0011392. Descrittori MeSH principali: Wolbachia; Onchocerciasis. Pagina: https://europepmc.org/article/MED/37428804 — https://doi.org/10.1371/journal.pntd.0011392. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T12:28:09.643Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.